Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine vs Sufentanil with Propofol for Sedation During ERCP
NCT07702240Not yet recruiting
- Sponsor
- Renda Biosciences
- Start
- Jul 2026
- Primary completion
- Mar 2028
01
Overview
Randomised trial of esketamine in biliary tract diseases (2 arms), sponsored by Renda Biosciences. Primary endpoint: Incidence of intraoperative hypoxemia. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
biliary tract diseases
Beyond the preview
Go deeper on NCT07702240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07702240.